Windward Bio

Healthcare & Life Sciences

Recent Finacing

Series A

Recent Raise

$200M

Windward Bio is a clinical-stage drug development company focused on creating treatments for severe respiratory conditions, including asthma and COPD, using long-acting monoclonal antibodies and bispecifics.

Total Funding

$200M

Headquarters

Switzerland

Founded

N/A

Website

windwardbio.com

Focus Areas

Drug development

respiratory conditions

monoclonal antibody

severe asthma

COPD

bispecifics

Investors